RESUMO
Multiplexed protein analysis using planar microarrays or microbeads is growing in popularity for simultaneous assays of antibodies, cytokines, allergens, drugs and hormones. However, this new assay format presents several new operational issues for the clinical laboratory, such as the quality control of protein-microarray-based assays, the release of unrequested test data and the use of diagnostic algorithms to transform microarray data into diagnostic results.
Assuntos
Biomarcadores/análise , Técnicas de Diagnóstico Molecular , Análise Serial de Proteínas , Kit de Reagentes para Diagnóstico , Algoritmos , Animais , Pesquisa Biomédica/ética , Confidencialidade/ética , Interpretação Estatística de Dados , Humanos , Técnicas de Diagnóstico Molecular/ética , Valor Preditivo dos Testes , Análise Serial de Proteínas/ética , Análise Serial de Proteínas/métodos , Proteínas/análise , Controle de Qualidade , Kit de Reagentes para Diagnóstico/normas , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
Intellectual property rights are essential in today's technology-driven age. A strong intellectual property protection strategy is crucial in the bioinformatics and biochips technology spaces as monetary and temporal resources are tremendous in finding a blockbuster drug or gene therapy, as well as in deploying advanced biosensor and other medical systems. Current problems and intellectual property practice in the genomic space are presented and analyzed. Various strategy and solutions are proposed to guide bioinformatic and biochip companies in forming an aggressive strategy to protect one's intellectual property and competitive positioning.
